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Background: The use of opiates, particularly heroin, remains an important cause of morbidity and mortality. Half of
the deaths among heroin consumers are attributed to overdose. In response to this problem, overdose prevention
programs (OPPs) were designed. The objective of our study was to assess coverage of OPPs among the target
population in a specific Spanish region (Catalonia) and to identify characteristics related to attendance.
Methods: A cross-sectional survey recruited individuals from outpatient treatment centers (OTCs), therapeutic
communities (ThCs), and harm reduction facilities (HRFs) in Catalonia. From 513 participants, 306 opiate users and/
or injectors were selected for this study. Coverage was calculated as the proportion of subjects who declared
having participated in an OPP. A Poisson regression with robust variance was used to assess factors (socio-demographic
aspects and psychoactive substance use patterns) associated to OPP participation, taking into account recruitment
strategy.
Results: Average age of the 306 subjects was 39.7 years (s.d.: 7.7); 79% were male; 79.2% lived in urban areas and
56.3% were unemployed or had never worked. Overall OPP coverage was 43.5% (95% CI: 37%–49%). Training was
received mostly in HRF (60%), followed by OTC (24.4%), prison (19%), and ThC (16%). OPP sessions were attended by
41% of Spanish-born study participants and by 63.3% of foreigners; 92.2% of the participants lived in urban areas. The
Poisson regression analysis adjusted by age, sex, and type of recruitment center showed that OPP participation rates
were higher for individuals with foreign nationality (PR = 1.3; 95% CI: 1.04–1.72), for those living in municipalities with
more than 100,000 inhabitants (PR = 2.0; 95% CI: 1.37–2.81) or the Barcelona conurbation (PR = 2.5; 95% CI: 1.68–3.77),
and for those having ever been in prison (PR = 1.6; 95% CI: 1.41–1.81) and had first consumption when they were less
than 12 years old (PR = 1.2; 95% CI: 1.06–1.45).
Conclusion: Coverage as a whole can be considered high. However, in Catalonia, new strategies ought to be
developed in order to attract opiate users and injectors not currently participating, by expanding OPP offer to
services and regions where coverage is poor.
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Antecedentes: El uso de opiáceos, sobre todo heroína, sigue siendo una causa importante de morbilidad y
mortalidad. La mitad de las muertes entre consumidores de heroína se atribuyen a sobredosis. Como respuesta a
este problema, se desarrollaron los Programas de Prevención de Sobredosis (PPS). El objetivo fue evaluar la
cobertura de PPS e identificar las características relacionadas con la asistencia.
Métodos: Estudio transversal de consumidores reclutados en Centros de Tratamiento (CT), Comunidades
Terapéuticas (CoT) y Centros de Reducción de Daños (CRD) en Cataluña (España). A partir de 513 participantes,
se seleccionaron 306 consumidores de opiáceos y/o inyectores. La cobertura fue calculada como la proporción de
sujetos que declararon haber participado en un PPS. Se realizó una regresión de Poisson con varianza robusta para
evaluar los factores (aspectos socio-demográficos y patrones de consumo de drogas), asociados a la participación
en PPS teniendo en cuenta la estrategia de reclutamiento.
Resultados: La edad media fue de 39.7 años (de: 7.7); 79% eran hombres; 79.2% vivían en zonas urbanas y 56.3%
eran desempleados o que nunca habían trabajado. En general, la cobertura de PPS fue del 43.5% (IC 95%:
37%-49%). La mayoría de los programas se realizaron en CRD (60%), seguido por CT (24.4%), cárcel (19%) y CoT
(16%). El 41% de los participantes nacidos en España participaron en un PPS mientras que lo hicieron un 63.3%
de los extranjeros; el 92.2% de los participantes vivían en zonas urbanas. Se realizó regresión de Poisson para el
análisis, ajustado por edad, sexo y centro de reclutamiento. Se obtuvieron mayores tasas de participación en PPS
en personas nacidas en el extranjero (RP = 1.3; 95% IC: 1.04-1.72), residentes en municipios con más de 100.000
(RP = 2.0; 95% IC: 1.37-2.81) y Barcelona conurbación (RP = 2.5; 95% IC: 1.68-3.77), en aquellos que habían estado
alguna vez en la cárcel (RP = 1.6; 95% IC: 1.41-1.81) y en los que hicieron el primer consumo con menos de 12 años
(RP = 1.2; 95% IC: 1.06-1.45).
Conclusión: La cobertura puede ser considerada alta, sin embargo en Cataluña nuevas estrategias deben ser
desarrolladas con el fin de atraer consumidores de opiáceos y/o inyectores que no participan, mediante la
ampliación de la oferta de PPS en los centros y las regiones donde la cobertura es deficiente.Background
Currently, substance abuse remains a huge public
health problem worldwide, despite different measures
having been undertaken in terms of prevention and
treatment for legal and illegal drugs [1]. It is estimated
that globally, over 27 million people are affected by
problematic consumption of some kind of substance
(0.6%). In numerous developed countries, illicit drug
use rates are alarming, opiates being one of main sub-
stances involved [1-4]. The European Commission and
the EU drugs agency (EMCDDA) have estimated that
in 2010, there were over 1.3 million active opiate users
in Europe [5] and the average prevalence of problem-
atic use is estimated to be between 3.9 and 4.4
individuals per 1,000 persons aged 15–64 years [2].
Furthermore, heroin has been classified as the second
most harmful psychoactive drug, taking into account
harm to self and others [6], and remains an important
cause of morbidity and mortality [2]. Different studies
have estimated that around half of the deaths of her-
oin consumers may be attributed to overdose [7], even
though a cohort study in Barcelona found that 34.7%
were due to opiate overdose, probably in relation to
the high AIDS-related mortality there [8]. However, it
has been estimated that only around 2%–3% of heroin
overdoses are fatal [9]. On the other hand, studies haveshown that the annual prevalence of non-fatal overdose
episodes is 9%–32% [9,10]. Even when non-fatal, they can
still have serious health consequences [10,11].
Circumstances and consequences of consumption
are almost always involved in heroin-related deaths
[12]. The risk of heroin overdose, whether fatal or
non-fatal, is related to factors such as parenteral route
of administration [13] and polydrug use [2,7], espe-
cially with central nervous system depressors (e.g.
alcohol, benzodiazepines) [10,14,15]. Using heroin
when alone and using heroin after a period of abstin-
ence have been established as risk factors for fatal opi-
ate overdose [12,16].
To reduce the health impact that heroin use entails, dif-
ferent strategies have been developed. In several countries,
treatment and prevention programs were set up to dimin-
ish heroin-associated harm and mortality [7,14]. Among
other therapeutic approaches, substitution treatment pro-
grams have been highly valuable, with methadone substi-
tution being one of the most widely employed. Methadone
maintenance programs have been shown to reduce inci-
dence of both fatal and non-fatal heroin overdoses [8,17].
Despite the effectiveness of these programs, a considerable
number of heroin addicts, whether or not enrolled in
them, continue heroin use and thus remain at an in-
creased risk of suffering from health problems, including
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duce fatal and non-fatal consequences of heroin use. They
include needle exchange programs, safe injection sites,
naloxone distribution, and overdose prevention programs
(OPPs) [14].
Accidental overdoses usually occur in the company
of peers whose immediate help may be critical to as-
sist the overdose victim. Furthermore, as death from
overdose usually occurs within 1–3 h after heroin in-
jection [14,18], there is time to act in order to avoid
the opiate poisoning being fatal. This fact led to the
development of overdose prevention programs (OPPs),
special courses designed [14,18] to teach opiate users
how to avoid suffering an overdose and train them in
treating those of their peers [19]. The OPP consist of
explaining the risks and consequences of opiate use, as
well as teaching participants to recognize signs of
overdose, how to deal with an overdose step by step,
and instruction in cardiopulmonary resuscitation tech-
nique and naloxone administration [14,19-21]. Nalox-
one as an opiate antagonist is very useful to reverse an
opiate overdose and as several feasibility studies have
demonstrated its effectiveness [22], training in its ad-
ministration has been incorporated into OPP. Prior
studies have shown that drug users trained in OPP are
very effective in recognizing overdose signs and in re-
ducing overdose deaths [23].
In Catalonia (Spain), opiate use by injection con-
tinues to be prevalent [24]. The region has been iden-
tified as having a high mortality rate for opiate
overdose [25]. Many treatment and prevention pro-
grams started first in Barcelona and subsequently
expanded, mainly to other urban areas. Implementa-
tion of OPP appears to have followed a similar pattern
until their systematic application started, first in cen-
ters where harm reduction programs are offered
(2009), followed by therapeutic communities (2010)
and outpatient treatment centers (2011) [XM, per-
sonal communication]. These programs last around
1 h and participants receive an economic reward.
Coverage of these programs needs to be evaluated in
order to guarantee their adequacy [23]. In this sense,
the main aim of the present study was to assess cover-
age of OPPs among the target population and to iden-
tify characteristics related to attendance.
Methods
Study design and sample
The sample for this cross-sectional study was recruited
in treatment and prevention centers in Catalonia (Spain)
between April and June 2012. A total of 48 centers were
selected: 26 outpatient treatment centers (OTCs), 12
therapeutic communities (ThCs), and 10 harm reduction
facilities (HRFs). Sampling was planned to cover thewhole territory, each center was required to recruit a
number of participants determined based on their activ-
ity, over-sampling the smallest selected centers, espe-
cially HRF. In OTC, this was done only for those having
more than 45 annual patients; and in each OTC, a
convenience sample was selected, taking into account
whether first treatment and time in treatment. Approval
for the study was obtained from the IMIM (Hospital del
Mar Medical Research Institute) ethics committee, and
ethical procedures were followed for data collection.
Participants were informed of the purpose of the study,
and HRF clients were rewarded with 10 €.
From a sample of 513 drug users (N approached =
564; participation rate: 91%), the target population was
selected for the present study, consisting of 312 opiate
(i.e. heroin, methadone) users and/or injectors. Partici-
pants answered a 78-item questionnaire involving single
or multiple-choice answers and different levels of com-
plexity. It was clearly structured and asked for informa-
tion about socio-demographic aspects, drug patterns,
illegal drug market activities, violence, health status, and
evaluation of prevention programs. Most questionnaires
were administered by a previously trained interviewer; a
minority of participants completed the questionnaires
themselves. Only four participants did not answer ques-
tions about participation in OPPs and two didn’t know
about participation (1.9% of the target population).
Therefore the final sample consisted on 306 opiate users
and/or injectors.
The coverage of OPPs was calculated for the total
sample, by recruitment center, region, and municipal-
ities, as the proportion of subjects who declared having
participated in an OPP. Variables of interest for OPP
participation analysis were recruitment center, socio-
demographic aspects (sex, age, country, municipality,
level of education, employment status, and sentenced
to prison), and psychoactive substance use patterns
(age at first drug use, first drug used, parenteral ad-
ministration, heroin and cocaine use, alcohol risk
consumption, and binge drinking). Alcohol risk con-
sumption was assessed through the AUDIT, short
version [26]. Other variables of interest were those re-
lated to OPPs (type of training center and when they
had attended OPP).
Statistical analyses
Poisson regression models with robust variance were
used to analyze association of OPP attendance with the
other variables mentioned above via prevalence ratios
(PR), adjusted by sex and age [27]. In addition, corre-
lated observations according to the type of recruitment
center (HRF, OTC, or ThC) were taken into account
through the generalized estimating equation procedure.
Analyses consisted in two steps. Firstly, we used distinct
Table 1 Overdose prevention program (OPP) coverage by
recruitment center and geographical area
Attendance to OPP
N Yes
Recruitment center 306 n % 95% CI
Outpatient treatment center 156 50 32.1 (27%–37%)
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non-attendance in OPP as the reference category. Later,
those variables with p-value <0.2 were included in a
multiple Poisson regression. Final model was fitted using
a backward procedure. Statistical significance was set at
p-value <0.05. All analyses were performed using PASW
Statistics version 18.Therapeutic communities 54 19 35.2 (30%–41%)
Harm reduction facilities 96 64 66.7 (61%–72%)
Municipality 305
Barcelona 130 66 50.8 (45%–56%)
BMC 49 29 59.2 (54%–65%)
More than 100,000 inhabitantsa 63 27 42.9 (37%–49%)
10,001 to 100,000 inhabitantsa 37 9 24.3 (19%–29%)
Up to 10,000 inhabitantsa 26 2 7.7 (5%–11%)
Provinces 300
Barcelona and BMC 176 92 52.3 (47%–58%)
Barcelonaa 56 19 33.9 (29%–39%)
Tarragona 28 4 14.3 (10%–18%)
Lleida 20 10 50 (44%–56%)
Girona 20 5 25 (20%–30%)
BMC Barcelona metropolitan conurbation.
aWithout Barcelona or BMC.Results
Among the 306 participants, 68.3% were opiate users
and injectors, 28.4% were only opiate users, and 3.3%
only injectors. The majority of participants were male
(79.2%). The average age was 39.7 years (s.d.: 7.7) (range:
20–71). Only 24% had high school or university degree.
Over half of the participants had never worked or were
unemployed (56.3%), 26.2% received a pension or had
some permanent disability, and 12% were currently
working; 57.3% of participants had a prison history. Re-
garding drug use patterns, alcohol risk consumption was
observed in 45.4% of study participants; 18% started il-
legal drug use when they were under 13 years old; and
in 76.3%, the first illegal drug used was cannabis.
One hundred thirty-three study participants had par-
ticipated in some OPPs (43.5%; 95% CI: 37%–49%). No
significant differences were found in the distribution of
OPP participation by either sex (men 44.6% vs women
39%) or age (mean age of OPP participants: 39.4 years s.
d.: 7.1); 66.7% of participants recruited in HRF had
attended an OPP, while only around one-third of indi-
viduals recruited in OTC and ThC had done so (Table 1).
OPP coverage by geographical area shows that people
living in Barcelona city or Barcelona metropolitan con-
urbation (BMC) had the highest participation (52.3%)
(Table 1). Related to time of attendance, 63.4% had
attended within the last 2 years, 19.1% between 2–5
years ago, and 17.6% more than 5 years ago. Among 131
OPP participants reporting where they had received
training, 60% did so in HRF, 24.4% in OTC, 19% in
prisons, and 16% in ThC (note that they could have
attended an OPP several times).
Regarding the associations in the bivariate analyses,
between OPP participation and other individual vari-
ables (Table 2), socio-demographic characteristics
found to be significantly associated to OPP attendance
were: being a foreigner (PR = 1.5; 95% CI: 1.12–2.03);
municipality, as residents from Barcelona and towns
of more than 100,000 habitants had a higher participa-
tion; employment status as individuals with permanent
disability or receiving a pension were more likely to have
attended an OPP and also prison as persons who had ever
been sentenced to prison declared a higher participation.
Regarding drug use-related variables, we found that partic-
ipants aged 12 years or under when they first used drugswere more likely to have enrolled in OPP (PR = 1.4; 95%
CI: 1.19–1.75).
The multiple Poisson regression analysis showed that
being a foreigner was associated to a greater chance of
participating (PR = 1.3; 95% CI: 1.04–1.72), as was resid-
ing in a town with more than 100,000 habitants (PR =
2.0; 95% CI: 1.37–2.81) or the Barcelona conurbation
(PR = 2.5; 95% CI: 1.68–3.77); also, individuals ever sen-
tenced to prison were more likely to have participated in
OPP (PR = 1.6; 95% CI: 1.41–1.81), as were subjects
whose first drug use was when they were 12 years old or
under (PR = 1.2; 95% CI: 1.06–1.45).
Discussion
Participation in overdose prevention programs by the
target study population was high, 43.5%. Coverage was
higher in Barcelona city and its conurbation. Character-
istics of participants associated to higher participation in
OPP in Catalonia were: residing in metropolitan areas,
being a foreigner, having been in prison, and starting
consumption at age 12 years or under.
In this study, an attempt was made to achieve maximum
representativeness of the target population, selecting
participants from all over Catalonia, but as recruitment
was only done in health centers, results can at most be
representative of drug users in healthcare settings. We
need to assume that the interviewed users are similar to
their peers. Injectors not reporting opiate use were also
Table 2 Socio-demographic and psychoactive substance use patterns associated to participation in overdose
prevention programs (OPPs)
Attendance to OPP Bivariate poisson Multiple poisson
Regressiona Regressiona
N Yes PR 95% CI PR 95% CI
n %
Socio-demographic characteristics
Country of origin 306
Spain 273 112 41 1 1
Other countriesb 33 21 63.6 1.5 (1.12–2.03)* 1.3 (1.04–1.72)*
Municipality 305
Less than 100,000 inhabitants; not BMC 63 11 17.5 1 1
More than 100,000 inhabitants; not BMC 52 20 38.5 2.2 (1.49–3.23)* 2.0 (1.37–2.81)*
Barcelona and BMC 190 102 53.7 3.1 (1.98–4.84)* 2.5 (1.68–3.77)*
Level of education 306
High school/university degree 73 26 35.6 1
Secondary education 121 55 45.5 1.3 (0.87–1.81)
Primary/elementary 112 52 46.4 1.3 (1.01–1.89)*
Employment status 302
Working 36 7 19.4 1
Never worked/unemployed 170 77 45.3 2.4 (0.95–6.02)
Permanent disability/pensioner 79 40 50.6 2.9 (1.23–6.60)*
Student/sporadic work/working at home 17 8 47.1 2.6 (0.67–10.10)
Ever sentenced to prison 304
No 131 36 27.5 1 1
Yes 173 95 54.9 2.0 (1.78–2.30)* 1.6 (1.41–1.81)*
Psychoactive substance use patterns
Age at first drug use 305
≥13 years 249 100 40.2 1 1
≤12 years 56 33 58.9 1.4 (1.19–1.75)* 1.2 (1.06–1.45)*
First drug used 304
Cannabis (marijuana, hashish) 232 101 43.5 1
Cocaine, heroin, her-coca, crack 48 23 47.9 1.1 (0.88–1.44)
Other drugsc 24 8 33.3 0.8 (0.40–1.43)
Parenteral administration 306
No 87 31 35.6 1
Yes 219 102 46.6 1.3 (1.03–1.70)*
Heroin use 306
No 16 7 43.8 1
Yes 290 126 43.4 1.0 (0.70–1.47)
Alcohol risk consumptiond 306
No 167 73 43.7 1
Yes 139 60 43.2 0.9 (0.75–1.24)
CI confidence interval, PR prevalence ratio, BMC Barcelona metropolitan conurbation.
*p <0.05.
aPoisson regression with robust variance adjusted by age and sex, using generalized estimated equations to control correlation within recruitment center.
bOther countries: rest of Europe, America, Asia, and North Africa.
cOther drugs: include tranquilizers, mushrooms, LSD, and ketamine.
dAccording to AUDIT [26].
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drug use in Catalonia is strongly associated with heroin
use [24]. Nevertheless, the resulting sample might be too
small to assess coverage precisely or to ascertain the asso-
ciation of some variables. Another limitation would be re-
lated to information and recall biases as reporting could
be influenced by desirability responses. However, some
drug user studies have shown that cross-sectional results
are valid despite being self-reported [28].
To our knowledge, no other studies have investigated
the coverage of overdose prevention programs in a given
geographical area. Coverage of other harm reduction
strategies in Spain was ascertained by Barrio et al., con-
cluding that implementation of such strategies arrived
late [29]. OPP could not be examined at that point but
as, in Catalonia, their systematic implementation did not
begin until 2009, we can affirm that they also arrived
late. However, in the present study, estimated mean
coverage was above 40%, considered high by WHO,
UNODC, and UNAIDS Technical Guide for clients of
harm reduction programs receiving information, educa-
tion, and communication [30]. Nevertheless, in this
study, we found that some non-systematic provision of
such programs took place in our region before 2009. In
this respect, we would like to emphasize the importance
of systematic implementation of these programs as al-
most two-thirds (63%) of the study participants had
done so in the years when it was systematic. In 2009,
programs were regulated in terms of education materials
(e.g. videos) and professional training; however, data
from the present study reflects the progressive incorpor-
ation of HRF, ThC, and OTC, participation being high
only in HRF.
OPP coverage by regions and municipalities was un-
equal. It was much higher in large cities, not only Barce-
lona city and conurbation; as other cities with more than
100,000 inhabitants had a coverage of nearly 43% which
could be considered high. In Catalonia, HRF are mainly
located in large metropolitan areas. As in other places
[31], the higher concentration of drug users in large
urban areas prompted the setting up of these preventive
interventions there. Starting OPP in HRF may also be
considered coherent with the perceived need of OPP
there, as such facilities take care of users currently using
the drug. Nevertheless, such interventions should also
be offered in OTC, ThC, and prisons in order to prevent,
and provide the skills to assist, unexpected overdoses
when resuming after a period of abstinence [32,33]. The
fact that more of our subjects recruited in HRF declared
having participated in OPP and that HRF were the
facilities where higher OPP attendance was reported by
participants is a consistent finding (the type of center
where subjects had received the OPP was correlated
with recruitment center, data not shown).OPP is considered an important support tool for over-
dose prevention policies which aim at reducing or avoid-
ing deaths or health consequences. Previous studies have
looked at the effectiveness of OPP, evaluating knowledge,
skills learned, and drug prescription among attendants
[22,34,35]. Different studies indicate that the vast major-
ity of participants are ready to cope with an overdose
after having participated in an OPP [36,23]. One study
found that 96% of drug users who were trained to iden-
tify overdose risk symptoms and administer naloxone
treatment reported positive outcomes, such as avoiding
death, coma, and brain damage [37]. Naloxone training
is considered a very effective preventive measure within
OPPs [23,19]. Other studies have found that over half of
the participants acquired knowledge and skills sufficient
to perform rescue breathing in an overdose situation
[37,38]. The satisfaction of participants in OPP has been
also assessed in some studies, finding them enthusiastic
about these training programs [39] and that they feel
grateful for and comfortable using the skills and tools
acquired [18]. Unfortunately, in our region, there has
been no evaluation of how many overdoses may have
been prevented after OPP implementation.
In Catalonia, between 2009 and 2011, a total of 2,681
drug users participated in OPPs. It is interesting to note
that in this study, people born abroad, with prison ante-
cedents and those who initiated consumption early (aged
under 13), reported more participation in OPP. Nearly
half of the OPP participants in this study were recruited
in HRF, and although recruitment center was controlled
for in the regression analysis, participants’ characteristics
are more similar to clients from HRF. Taking into ac-
count that HRF started OPP earlier, they are located in
large cities, and most of them are open all day; such re-
sults were not unexpected. Some of the services offered
in these centers, such as the so-called ‘calor-café,’ tend to
attract drug users with social problems or other hard-
ship, by allowing them to remain on the premises for a
while, thus favoring their enrollment in preventive pro-
grams. This population may include immigrants and
people who have been in prison. HRFs may be the first
point of contact with healthcare centers and treatment
for people born abroad [40,41]. They may also be rele-
vant for released prison inmates who learnt about the
importance of harm reduction strategies while in prison
[16,33,42]. As a whole, according to these results, so far
OPPs have mainly focused on the needs of the most so-
cially excluded, attracted by HRF, than on those of indi-
viduals having more theoretical risk (for example, drug
users in OTC).
Conclusions
Our study allowed assessing OPP coverage in Catalonia,
showing that although as a whole the coverage can be
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medium-poor coverage. Characteristics of OPP attenders
paralleled those of HRF users, as subjects recruited there
were more prone to have participated. New strategies
would need to be developed to attract the target popula-
tion by offering more OPP in services and regions where
participation is poor and assessing why Spaniards have
lower involvement in these programs.
Abbreviations
BMC: Barcelona metropolitan conurbation; CI: Confidence interval; HRF: Harm
reduction facilities; OPP: Overdose prevention programs; OTC: Outpatient
treatment centers; PR: Prevalence ratio; ThC: Therapeutic communities;
UNAIDS: United Nations and AIDS; UNODC: United Nations Office on Drugs
and Crime; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors participated in the study design. EAI and ASN conducted the
statistical analysis. EAI together with TB and ADS interpreted the results. EAI
drafted the first manuscript that was subsequently revised and approved by
all authors. All authors read and approved the final manuscript.
Acknowledgements
Funding for this study was provided by the Spanish Government Grant:
Instituto de Salud Carlos III-FIS PI11/01358. Further financial support was
provided by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR
2009 SGR 718) and FIS-Redes de investigación cooperativa RD12/0028/0018.
We give our thanks to the participants, the collaborating centers, and their
professionals. We are also grateful to Dave Macfarlane for editing and English
revision.
Author details
1Research group of drug abuse epidemiology, IMIM—Institut Hospital del
Mar d’Investigacions Mèdiques, Doctor Aiguader 88, E-08003 Barcelona,
Spain. 2Public Health Agency of Catalonia, Edifici Salvany, Roc Boronat 81-95,
08005 Barcelona, Spain. 3Public Health Agency of Barcelona, Pl. Lesseps 1,
08023 Barcelona, Spain.
Received: 31 October 2013 Accepted: 7 November 2014
Published: 22 November 2014
References
1. European Monitoring Centre for Drugs and Drug Addiction: Annual Report
2009. The State of the Drug Problem in Europe. Luxembourg: Publications
Office of the European Union; 2009.
2. European Monitoring Centre for Drugs and Drug Addiction: Annual report
2012: The state of the drugs problem in Europe. Luxembourg: Publications
Office of the European Union; 2012.
3. United Nations Office on Drugs and Crime: World drug report 2012. Vienna; 2012.
4. United Nations Office on Drugs and Crime: World drug report 2013. Vienna; 2013.
5. Strang J, Groshkova T, Metrebian N: Insights. Lisbon: New heroin assisted-
treatment. Recent evidence and current practices of supervised injectable
heroin treatment in Europe and beyond. European Monitoring Centre for
Drugs and Drug Addiction; 2013.
6. Nutt DJ, King LA, Phillips LD: Drug harms in the UK: a multicriteria
decision analysis. Lancet 2010, 376:1558–1565.
7. Darke S, Hall W: Heroin overdose: research and evidence-based intervention.
J Urban Health 2003, 80:189–200.
8. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, de Garcia OP, de la Fuente
L: Evaluating the impact of methadone maintenance programmes on
mortality due to overdose and aids in a cohort of heroin users in Spain.
Addiction 2005, 100:981–989.
9. Darke S, Ross J, Hall W: Overdose among heroin users in Sydney,
Australia: II. Responses to overdose. Addiction 1996, 91:413–417.10. Brugal MT, Barrio G, De LF, Regidor E, Royuela L, Suelves JM: Factors
associated with non-fatal heroin overdose: assessing the effect of fre-
quency and route of heroin administration. Addiction 2002, 97:319–327.
11. Gossop M, Griffiths P, Powis B, Williamson S, Strang J: Frequency of non-
fatal heroin overdose: survey of heroin users recruited in non-clinical set-
tings. BMJ 1996, 313:402.
12. Cami J, Domingo-Salvany A: Factores de riesgo en la muerte por heroína.
The risk factors in death from heroin. Med Clin (Barc) 1995, 105:455–456.
13. Miller PG: Safe using messages may not be enough to promote
behaviour change amongst injecting drug users who are ambivalent or
indifferent towards death. Harm Reduct J 2009, 6:18.
14. Sporer KA: Strategies for preventing heroin overdose. BMJ 2003,
326:442–444.
15. Sporer KA: Acute heroin overdose. Ann Intern Med 1999, 130:584–590.
16. Binswanger IA, Blatchford PJ, Mueller SR, Stern MF: Mortality after prison
release: opioid overdose and other causes of death, risk factors, and
time trends from 1999 to 2009. Ann Intern Med 2013, 159:592–600.
17. Torrens M, Fonseca F, Castillo C, Domingo-Salvany A: Methadone maintenance
treatment in Spain: the success of a harm reduction approach. Bull World
Health Organ 2013, 91:136–414.
18. Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J,
Ciccarone D, Edlin BR: Attitudes about prescribing take-home naloxone to
injection drug users for the management of heroin overdose: a survey
of street-recruited injectors in the San Francisco Bay area. J Urban Health
2003, 80:291–301.
19. Neira-Leon M, Barrio G, Bravo MJ, Brugal MT, de la Fuente L, Domingo-Salvany
A, Pulido J, Santos S, Project Itinere Group: Infrequent opioid overdose risk
reduction behaviours among young adult heroin users in cities with wide
coverage of HIV prevention programmes. Int J Drug Policy 2011, 22:16–25.
20. Heller DI, Stancliff S: Providing naloxone to substance users for secondary
administration to reduce overdose mortality in New York City. Public
Health Rep 2007, 122:393–397.
21. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S: Prescribing naloxone
to actively injecting heroin users: a program to reduce heroin overdose
deaths. J Addict Dis 2006, 25:89–96.
22. Dettmer K, Saunders B, Strang J: Take home naloxone and the prevention of
deaths from opiate overdose: two pilot schemes. BMJ 2001, 322:895–896.
23. Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley
JH, Gonzalez M, Unger JB: Evaluation of an overdose prevention and
response training programme for injection drug users in the Skid Row
area of Los Angeles, CA. Int J Drug Policy 2010, 21:186–193.
24. Observatorio Español de la Droga y las Toxicomanías: Informe 2011.
Situación y tendencias de los problemas de drogas en España. Delegación del
Gobierno para el Plan Nacional sobre Drogas. Madrid: Ministerio de Sanidad
y Política Social; 2011.
25. Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal
T, Vicente J, COSMO European Group: Drug-related mortality and its
impact on adult mortality in eight European countries. Eur J Public Health
2006, 16:198–202.
26. Contel M, Gual A, Colom J: Test para la identificacion de trastornos por
uso de alcohol (AUDIT): traduccion y validacion del AUDIT al catalan y
castellano. Addicciones 1999, 11:337–347.
27. Coutinho LM, Scazufca M, Menezes PR: Methods for estimating
prevalence ratios in cross-sectional studies. Rev Saude Publica 2008,
42:992–998.
28. Maisto SA, McKay JR, Connors GJ: Self-report issues in substance abuse:
state of the art and future directions. Behav Assess 1990, 12:117–134.
29. Barrio G, Bravo MJ, Brugal MT, Diez M, Regidor E, Belza MJ, de la Fuente L,
Itinere Working Group: Harm reduction interventions for drug injectors or
heroin users in Spain: expanding coverage as the storm abates. Addiction
2012, 107:1111–1122.
30. World Health Organization, United Nations Office on Drugs and Crime, United
Nations AIDS: Technical Guide for countries to set targets for universal access to
HIV prevention, treatment and care for injecting drug users. Geneva; 2009.
31. World Health Organization: Effectiveness of sterile needle and syringe
programming in reducing HIV/AIDS among injecting drug users. Geneva; 2004.
32. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M,
Salamina G, Diecidue R, Vigna-Taglianti F, Faggiano F, VEdeTTE Study Group:
Risk of fatal overdose during and after specialist drug treatment: the
VEdeTTE study, a national multi-site prospective cohort study. Addiction
2007, 102:1954–1959.
Arribas-Ibar et al. Harm Reduction Journal 2014, 11:33 Page 8 of 8
http://www.harmreductionjournal.com/content/11/1/3333. Hakansson A, Berglund M: All-cause mortality in criminal justice clients
with substance use problems—a prospective follow-up study. Drug
Alcohol Depend 2013, 132:499–504.
34. Green TC, Heimer R, Grau LE: Distinguishing signs of opioid overdose and
indication for naloxone: an evaluation of six overdose training and
naloxone distribution programs in the United States. Addiction 2008,
103:979–989.
35. Piper TM, Rudenstine S, Stancliff S, Sherman S, Nandi V, Clear A, Galea S:
Overdose prevention for injection drug users: lessons learned from
naloxone training and distribution programs in New York City. Harm
Reduct J 2007, 4:3.
36. Frisher M, Baldacchino A, Crome I, Bloor R: Preventing Opioid Overdoses in
Europe: A Critical Assessment of Known Risk Factors and Preventative
Measures. EMCDDA, Lisbon: European Monitoring Centre for Drugs and
Drug Addiction Technical paper; 2012.
37. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH: Characteristics of an
overdose prevention, response, and naloxone distribution program in
Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 2011,
88:1020–1030.
38. Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, Bamberger JD:
Overdose prevention and naloxone prescription for opioid users in San
Francisco. J Urban Health 2010, 87:931–941.
39. Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT:
Client satisfaction among participants in a randomized trial comparing
oral methadone and injectable diacetylmorphine for long-term
opioid-dependency. BMC Health Serv Res 2011, 11:174.
40. Anton JI, de Munoz BR: Health care utilisation and immigration in Spain.
Eur J Health Econ 2010, 11:487–498.
41. Saigi N, Espelt A, Folch C, Sarasa-Renedo A, Castellano Y, Majo X, Meroño M,
Brugal MT, Casabona J, REDAN Group: Differences in illegal drug consumption
between native and immigrants in a large sample of injected drug users in
Catalonia (Spain). Adicciones 2014, 26:69–76.
42. Huang YF, Kuo HS, Lew-Ting CY, Tian F, Yang CH, Tsai TI, Gange SJ, Nelson
KE: Mortality among a cohort of drug users after their release from
prison: an evaluation of the effectiveness of a harm reduction program
in Taiwan. Addiction 2011, 106:1437–1445.
doi:10.1186/1477-7517-11-33
Cite this article as: Arribas-Ibar et al.: Coverage of overdose prevention
programs for opiate users and injectors: a cross-sectional study. Harm
Reduction Journal 2014 11:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
